By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – SuperNova Diagnostics today said that it has signed a collaboration agreement with Shenzhen Kang Bao Bio-Technology.

The Germantown, Md.-based startup did not say what functions KSB Diagnostics will be performing on its behalf, but noted that the Hong Kong firm specializes in the research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and other markets in the area.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.